Abstract
Protection of the brain is strengthened by active transport and ABC transporters. P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a substrate from the brain, which is important for maintaining loco-regional homeostasis in the brain and protection against toxic compounds. Importantly, dysfunctional BBB P-gp transport is postulated as an important factor contributing to accumulation of aggregated protein in neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD). Furthermore, P-gp is a major factor in mediating resistance to brain entry of numerous exogenous compounds, including toxins that can be involved in PD pathogenesis. This review highlights the role of altered P-gp function in the pathogenesis and progression of neurodegenerative disease. Also the implications of alterations in P-gp function for the treatment of these diseases are discussed.
Keywords: Blood-brain barrier, P-glycoprotein, [11C]-verapamil PET, Parkinson, Alzheimer, Microglia, pesticides, olfactory neurons, progressive supranuclear palsy (PSP), mutation
Current Pharmaceutical Design
Title: Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Volume: 17 Issue: 26
Author(s): A.L. Bartels
Affiliation:
Keywords: Blood-brain barrier, P-glycoprotein, [11C]-verapamil PET, Parkinson, Alzheimer, Microglia, pesticides, olfactory neurons, progressive supranuclear palsy (PSP), mutation
Abstract: Protection of the brain is strengthened by active transport and ABC transporters. P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a substrate from the brain, which is important for maintaining loco-regional homeostasis in the brain and protection against toxic compounds. Importantly, dysfunctional BBB P-gp transport is postulated as an important factor contributing to accumulation of aggregated protein in neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD). Furthermore, P-gp is a major factor in mediating resistance to brain entry of numerous exogenous compounds, including toxins that can be involved in PD pathogenesis. This review highlights the role of altered P-gp function in the pathogenesis and progression of neurodegenerative disease. Also the implications of alterations in P-gp function for the treatment of these diseases are discussed.
Export Options
About this article
Cite this article as:
Bartels A.L., Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease, Current Pharmaceutical Design 2011; 17 (26) . https://dx.doi.org/10.2174/138161211797440122
DOI https://dx.doi.org/10.2174/138161211797440122 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors
Current Topics in Medicinal Chemistry Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Restriction Factors Against Recombinant Adeno-associated Virus Vectormediated Gene Transfer in Dystrophin-deficient Muscles
Current Gene Therapy Exploring the Benefits of Cellular Models to Uncover Bioactive Polyphenols for Neurodegeneration
Current Pharmaceutical Design VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design
Current Pharmaceutical Design Molecular Mechanisms Determining Opposed Functional States of Microglia
Current Neuropharmacology Interaction of Different Proteins with GABA<sub>A</sub> Receptor and their Modulatory Effect on Inhibitory Neural Transmission Leads to Epilepsy
CNS & Neurological Disorders - Drug Targets Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)
Current Cancer Drug Targets Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Nanotubes at Neural and Immune Synapses
Current Medicinal Chemistry Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals
Current Molecular Medicine TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Proteasome Inhibitors Therapeutic Strategies for Cancer
Recent Patents on Anti-Cancer Drug Discovery HspB5/αB-Crystallin: Properties and Current Progress in Neuropathy
Current Neurovascular Research Comparison of Mono-dopaminergic and Multi-target Pharmacotherapies in Primary Parkinson Syndrome and Assessment Tools to Evaluate Motor and Non-motor Symptoms
Current Drug Therapy Editorial [Hot topic: Central and Peripheral Metabolic Changes in Neurodegenerative Diseases (Guest Editor: Ana Cristina Rego)]
Current Drug Targets Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer’s disease
CNS & Neurological Disorders - Drug Targets Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets The Role of Microglial Cells on Neuroinflammation: Possible Therapeutic Applications
Recent Patents on Regenerative Medicine